Your browser doesn't support javascript.
loading
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
Busaidy, Naifa L; Konda, Bhavana; Wei, Lai; Wirth, Lori J; Devine, Catherine; Daniels, Gregory A; DeSouza, Jonas A; Poi, Ming; Seligson, Nathan D; Cabanillas, Maria E; Sipos, Jennifer A; Ringel, Matthew D; Eisfeld, Ann-Kathrin; Timmers, Cynthia; Shah, Manisha H.
Affiliation
  • Busaidy NL; Division of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konda B; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Wei L; Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Wirth LJ; Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Devine C; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daniels GA; Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, La Jolla, California, USA.
  • DeSouza JA; Division of Medical Oncology, The University of Chicago, Chicago, Illinois, USA.
  • Poi M; Department of Pharmacology, The Ohio State University, Columbus, Ohio, USA.
  • Seligson ND; Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
  • Cabanillas ME; Division of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sipos JA; Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Ringel MD; Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Eisfeld AK; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
  • Timmers C; Translational Sciences Discovery Lab, Incyte Corporation, Wilmington, Delaware, USA.
  • Shah MH; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Thyroid ; 32(10): 1184-1192, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35658604
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma / Melanoma Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Journal: Thyroid Journal subject: ENDOCRINOLOGIA Year: 2022 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Adenocarcinoma / Melanoma Type of study: Clinical_trials Limits: Adolescent / Adult / Humans Language: En Journal: Thyroid Journal subject: ENDOCRINOLOGIA Year: 2022 Document type: Article Affiliation country: United States